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doi:10.101Individualized Intervention Guided by BCR-ABL
Transcript Levels after HLA-Identical Sibling Donor
Transplantation Improves HSCT Outcomes for Patients
with Chronic Myeloid Leukemia
Xiao-Jun Huang, Lan-Ping Xu, Kai-Yan Liu, Dai-Hong Liu, Huan Chen, Yan-Rong Liu,
Yu-Hong Chen, Wei Han, Yu WangThe aim of this study was to determine the effect of individualized intervention guided by BCR-ABL transcript
levels after hematopoietic stem cell transplantation (HSCT) on relapse and leukemia-free survival (LFS) of
patients with chronic myelogenous leukemia (CML). Eighty-four consecutive patients who received HLA-
identical sibling HSCTwere enrolled. The patients were conditioned with a modified busulfan and cyclophos-
phamide regimen, and received stem cells from a HLA-identical sibling donor. Patients were identified as high
risk of relapse based on serial monitoring of post-HSCT BCR-ABL transcript levels, and patients in the high-
risk group were given individualized intervention. Interventions included immunosuppressant withdrawal,
modified donor lymphocyte infusion, and imatinib mesylate. Engraftment was successful in all patients.
Twenty-eight patients were categorized as high risk because of higher post-HSCT BCR-ABL transcript levels
and received intervention. The 56 low-risk patients received no intervention. Twenty-five high-risk patients
achieved complete molecular remission at a median of 49 days (range: 18-232 days) after intervention. Two
high-risk patients and 1 low-risk patient ultimately relapsed, the 4-year relapse rate was 3.9%6 4.4%. Overall
4-year survival was 89.0% 6 7% and the 4-year LFS was 89.2% 6 6.8%. All surviving patients remains in
completemolecular remission after a median of 1481 (1040-1794) days follow-up. Individualized intervention
based on the post-HSCT BCR-ABL transcript level can decrease relapse and increase LFS of patients with CML
after HLA-identical sibling HSCT.
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Therapy for chronic myelogenous leukemia (CML)
has changed considerably since the development of
specific BCR-ABL tyrosine kinase inhibitors such as
imatinib mesylate (IM). These new treatments have de-
creased the need for up-front allogeneic transplantation
in patients with CML [1,2]. Despite this, allogeneic
hematopoietic stem cell transplantation (allo-HSCT)
remains the only proven curative treatment forPeking University People’s Hospital, Peking University
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6/j.bbmt.2010.07.023patients with CML, and might be the only alternative
therapy for patients who develop resistance to
antityrosine kinase therapy [3-5]. In developing
countries such as China, HSCT plays an even more
important role partly because of patient preference and
economic feasibility.
Relapse, observed in 8% to 26% of patients with
chronic phase CML after matched sibling donor
HSCT, continues to be 1 of themain causes ofmorbid-
ity andmortality afterHSCT [2-5].Donor lymphocyte
infusion (DLI) and IM and immunosuppressant
withdrawal (IS-W) have been proven to be effective
therapies for patients who relapse after allo-HSCT
[6-9]. Whether early intervention with DLI or IM or
IS-W can improve the outcome of HSCT has never
been proven.
The level of BCR-ABL transcripts predicts the re-
sponse to tyrosine kinase inhibitors and the probability
of relapse after tyrosine kinase inhibitors [10]. The
kinetics of BCR-ABL transcription after HSCT has
not been fully studied, but several trials have suggested
that increasing BCR-ABL transcript numbers in the649
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[11,12]. In a previous study, we identified a group of
CML patients who were at low risk of relapse after
matched sibling donor HSCT. BCR/ABL transcript
levels decreased 2- to 3-log-fold in the first month
following HSCT and continued to decrease or
stabilize at a low level over the next 2 to 3 months,
becoming undetectable at a median of 4 months post-
HSCT [13]. Therefore, CML patients can be divided
into low- and high-risk groups based on serialmonitor-
ing of BCR-ABL transcript levels post-HSCT. Here,
we designed an open, prospective trial to test the hy-
pothesis that individualized intervention guided by
post-HSCT changes in BCR-ABL transcript levels
can decrease overall relapse and improve overall
leukemia-free survival (LFS) for patients with CML.PATIENTS AND METHODS
Eligibility Criteria
From November 2004 to June 2006, 84 consecu-
tive patients with CML who received matched sibling
HSCT were included in this study. Allogeneic HSCT
was chosen according to the intentions of patients who
have HLA-sibling donors. The protocols were ap-
proved by the institutional review board at Peking
University Institute of Hematology, and all patients
or their guardians signed consent forms approved by
the institutional review board. This study has been as-
signed in Chinese Clinical Trial Register (Registration
Number: ChiCTR-PNRC-00000307). The follow-up
period for the study ended October 1, 2009.
Donor Source and HLATyping
Polymerase chain reaction (PCR)-mediated mo-
lecular typing was performed for class I alleles
(HLA-A, -B) and class II alleles (HLA-DR B1) in
donor DNA. All donors were HLA-matched siblings.
Conditioning Regimen
The pretransplant conditioning regimen consisted
of hydroxyurea, 40 mg/kg every 12 hours for 1 day;
cytarabine, 2 g/m2/day for 1 day; BU, 4 mg/kg/day
orally or 3.2 mg/kg/day intravenously (i.v.,) for 3
days; CY 1.8 g/m2/day for 2 days; and, Me-CCNU
250 mg/m2 for 1 day.
Collection of Hematopoietic Cells
Donor stem cells were mobilized with recombi-
nant human granulocyte-colony stimulating factor
(G-CSF) (Filgrastim, Kirin, Japan) injected subcutane-
ously at 5 mg/kg daily for 5 consecutive days. Stem cells
from bone marrow (BM) were collected on the fourth
day of mobilization and peripheral blood stem cells
(PBSCs) were collected on the fifth day in cases ofcombined BM stem cells (BMSC) and PBSC trans-
plant. In case of PBSC transplant, PBSCs were col-
lected on the fourth and fifth days. BM was infused
into patients immediately after collection and PBSCs
were infused fresh and unmanipulated. In cases of
ABO major blood group incompatibility, red cells in
the marrow were removed by hydroxyethyl sediment
manipulation. In case of ABO minor blood group in-
compatibility, plasma in the marrow was removed by
centrifugation.
Graft-versus-Host Disease (GVHD) Prophylaxis
and Management
All patients were given a combination of cyclo-
sporine (CsA), and a short course of methotrexate
(MTX) and mycophenolate mofetil (MMF). MTX
was administered intravenously at 15 mg/m2 on day
11 and then 10 mg/m2 on days13 and16 after trans-
plantation. CsA (1.25 mg/kg twice a day i.v.) was
started on day –9 and was continued until patients
could tolerate oral medication. Thereafter, CsA was
given orally twice a day with trough levels targeted
to 150-250 ng/mL, then tapered based on the presence
or absence of severe GVHD. It is standard practice to
taper CsA gradually beginning at 3 months, complet-
ing withdrawal by 5 to 6 months posttransplantation.
MMF (1 g/day) was begun on day –9 and was discon-
tinued after engraftment. GVHD was treated with 1-2
mg/kg/day of methylprednisolone equivalents and
resumption of full-dose CsA therapy. Second-line im-
munosuppressive therapy, such as tacrolimus (FK506),
MMF, CD25 monoclonal antibody (Simulect, Novar-
tis), or MTX, was given for steroid refractory acute
GVHD (aGVHD).
Supportive Care
HSCT recipients were nursed in isolation rooms
with laminar airflow systems. Prophylactic trimetho-
prim/sulfamethoxazole, acyclovir, ganciclovir, and
fluconazole were administered to prevent infection by
Pneumocystis jiroveci, herpes simplex, cytomegalovirus
(CMV), and fungi. Patients were monitored weekly by
plasma Q-PCR for CMV DNA. Patients with CMV
viremiawere treatedwitheitherganciclovir or foscarnet.
Blood products were administered to patients with
hematocrit levels below 25% and/or platelet counts
below 20  109/L. All blood products were irradiated
prior to use.
Monitoring of Chimerism and Minimal Residual
Disease
Chimerism was evaluated on recipient BM cells at
11,12,13,16,19, and112 months after HSCT by
fluorescein in situ hybridization (FISH) or DNA fin-
gerprint analysis. As a rule, serial measurement of
BCR-ABL transcript levels in the BM after HSCT
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16, 19, and 112 months; the assay frequency was in-
creased as needed. BCR-ABL transcripts were tested by
real-time Q-RT/PCR using the TaqMan probe sys-
tem. The BCR-ABL mRNA level was normalized to
that of the control gene ABL and the reproducible
sensitivity of the PCR for BCR-ABL is 5 copies as
previously described [14-17].Evaluation and Definitions
The severity of aGVHD and chronic GVHD
(cGVHD) was determined according to the criteria
of Glucksberg et al. [18]. GVHD was diagnosed as
acute or chronic according to clinical features of the
affected organs rather than according to the time.
Relapse indicated hematologic relapse.
Complete molecular remission (CMR) was defined
as negative Q-RT/PCR for BCR-ABL in 3 consecutive
samples after initial positivity. A reduction in BCR-
ABL transcript levels of at least 3 log was used to define
a major molecular response [19-21]. A decline in the
BCR-ABL transcript level was defined as an at least
1-log decrease relative to baseline in 2 consecutive
tests over a period of 2 months.
Stable molecular disease was defined as a BCR-
ABL transcript level within 1-log of baseline in 2
consecutive samples.
A rise in the BCR-ABL transcript level was defined
as an increase of at least 1-log relative to baseline in 2
consecutive results over a period of 2 months.Definition of Low and High Risk of Patients
Low-risk patients were patients who satisfied any 1
of the following criteria:
(1) BCR-ABL mRNA levels were reduced at least 2
log frombaseline at 1monthpost-HSCTand continued
todecline thereafterwithin thefirst year afterHSCT, (2)
achieved MMR and had a stable BCR-ABL transcript
level within the first 3 months post-HSCT and contin-
ued to decline thereafter within the first year after
HSCT, (3) had grade II-IV aGVHD or extensive
cGVHD and stable or decreasing BCR-ABL transcript
levelswithin the first year afterHSCT,or (4)maintained
CMR within the first year after HSCT.
High-risk patients were those patients excluded
from the low-risk group.Interventions for High-Risk Patients
Patients with active GVHD and patients who were
no longer receiving CsA received IM as the primary
intervention; patients still receiving CsA and with no
GVHD received IS-W with or without IM as the pri-
mary intervention. Patients with no ‘‘good’’ response
(meaning no decline in BCR-ABL levels) to the for-
mer interventions at 1 month follow-up, receivedmodified donor lymphocyte infusion (mDLI) as sec-
ond intervention.
Protocol 1
IS-W included the rapid taper and discontinuation
of CsA ahead of the schedule.
Protocol 2
Imatinib therapy was initiated at 300 to 400 mg
daily for 4 to 12 months. IM dosage was decreased or
discontinued if a hematologic relapse or severe toxicity
occurred. The National Institutes of Health Common
Toxicity Criteria was used to define toxicity. In cases of
grades 2-4 nonhematologic toxicities lasting for more
than 2 days, IMwas withheld until a resolution to equal
to or less than grade 1. For patients who experienced
grade 3 or 4 hematologic toxicities, IM was withheld.
Protocol 3
mDLI was administered as references [8,9] show
when the patients showed no response to the first 2
therapies and no severe GVHD occurred. The
protocol of mDLI included 2 elements. (1) G-CSF-
primed peripheral blood progenitor cells (PBPCs)
instead of unprimed donor lymphocyte harvests were
used; and (2) short-term immunosuppressive agents
were used for the prevention of GVHD after DLI.
Statistical Analysis
Results as ofOctober 1, 2009,wereused for analysis.
Overall survival (OS) and LFS at 4 years post-HSCT
were theprimary endpointsof the study. Secondaryend-
points included relapse incidence, nonrelapse mortality
(NRM), treatment-related mortality (TRM), incidence
and severity of aGVHD and cGVHD, and quality of
life as measured by Karnofsky Performance Status. OS
and LFS were estimated using the Kaplan-Meier curve
method and the log-rank method was used to LFS be-
tween groups. The calculations were carried out using
SPSS 16.0 software. NCSS software was used to calcu-
late the cumulative incidences considering the presence
of competing risks.RESULTS
Patient Characteristics
Twenty-eight patients were assigned to the high-
risk group and received individualized intervention
and 56 patients were assigned to the low-risk group
(Table 1). In the high-risk group, prior HSCT treat-
ment include use of imatinib mesylate (7 cases), inter-
feron-a (8 cases), and hydroxyurea (10 cases), except
for 3 patients who received both imatinib mesylate
and interferon-a. Although in low-risk group prior
HSCT treatment included use of imatinib mesylate
Table 1. Patient Characteristics
Characteristic
High-Risk Group
(n 5 28)
Low-Risk Group
(n 5 56) P-Value
Sex (male/female) 22/6 43/13 .83
Age in years, median (range) 33 (12-51) 38 (21-50) .60
Median time from diagnosis to Transplant, median (range) (days) 150 (60-4745) 150 (60-2280) 0.92
Disease status prior to HSCT
CP1 24 52 .426
CP2 2 3
AP/BC 2 1
EBMT score (# of cases) .533
0sim1 9 13
2 12 33
3 5 6
>4 2 4
Stem cell source .555
BM 2 2
BM and PB 22 49
PB 4 5
Infused graft * .51
CD3 (108/kg) 1.68 (0.15-3.23) 1.67 (0.2-3.33)
CD4 (108/kg) 1.00 (0.08-2.61) 0.82 (0.1-2.11)
CD8 (108/kg) 0.67 (0.06-1.77) 0.66 (0.08-1.63)
CD34 (106/kg) 1.96 (0.28-8.12) 2 (0.54-8.48)
TNC (108/kg) 6.88 (4.04-12.35) 6.75 (3.38-13.53)
BCR-ABL*pre-HSCT (%) 34.88 (3.3-64.4) 27.81 (0.2-96.1) .36
HSCT indicates hematopoietic stem cell transplantation; CP1, first chronic phase; CP2, second chronic phase; AP, accelerated phase; BC, blast crisis;
EBMT, European Group for Blood and Marrow Transplantation; BM, bone marrow; PB, peripheral blood; TNC, total nucleated cells.
*Data are reported as median (range).
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cases), there was 1 patient who received both imatinib
mesylate and interferon-a.Engraftment
All patients achieved hematopoietic engraftment,
and full donor chimerism was confirmed by FISH
and/or DNA fingerprint analysis. The median times
to neutrophil and thrombocyte engraftment were 17
days (range: 11-24 days) and 13 days (range: 6-60
days), respectively.Intervention for High-Risk Patients
Themedian start time of interventions was day 90
post-HSCT (range: day 40-162). The numbers of pa-
tients in chronic phase (CP) 1, CP2, accelerated
phase, and blast crisis pre-HSCT were 24, 2, 1, and
1, respectively.Table 2. Intervention by mDLI
MNC Infused CD3+ T Cell Infused
1 2.8  108/kg 0.997  108/kg
2 1  108/kg 0.430  108/kg
3 2.0  108/kg
and 2.55  108/kg
0.82  108/kg
1.046  108/kg
4 2.0  108/kg
and 1.44  108/kg
0.800  108/kg 0.576  108/kg
5 2.0  108/kg 0.946  108/kg
6 3.5  108/kg 2.004  108/kg
MNC indicates mononuclear cells; GVHD, graft-versus-host disease; CsA, cy
infusion.Of the 22 patients receiving IS-W, 16 patients de-
velop GVHD: grade II aGVHD 1, grade III aGVHD
2, local cGVHD 5, and extensive cGVHD 8. The me-
dian time from CsA withdrawal to GVHD onset was
14 days (range: 10-52 days). Fifteen patients received
CsA with or without prednisone for intervention-
induced GVHD and GVHD was well controlled.
Among these patients, 1 patient with grade II aGVHD
and 5 patients with local cGVHD received CsA (blood
concentration of 150-250 ng/mL) only, 2 patients with
grade III aGVHD received CsA and prednisone (1mg/
kg), and 8 patients with extensive cGVHD received
CsA and prednisone (0.5-1.0 mg/kg).
Thirteen patients began IM therapy at a median of
102 days post-HSCT (range: 34-210 days). Hemato-
logic toxicities occurred in 5 patients (grade I: 1; grade
II; 2; and grade III-IV: 2 patients) and recovered com-
pletely after dosage adjustment or drug discontinua-
tion, except for 1 patient who had graft failure after
imatinib and received a second transplantation.Prophylaxis of GVHD Pancytopenia GVHD
CSA NO II
MTX NO 0
MTX NO 0
MTX NO 0
MTX NO 0
MTX NO 0
closporine A; MTX, methotrexate; mDLI, modified donor lymphocyte
Table 3. Clinical Outcomes
High-Risk Group
(n 5 28)
Low-Risk Group
(n 5 56) P-Value
II-IV aGVHD (%)* 24.3 ± 8.5 24.4 ± 5.9 .917
III-IV aGVHD* 9.1 ± 6.1 9.2 ± 3.9 .707
Extensive cGVHD (%)† 28.57 ± 8.54 29.36 ± 6.18 .643
TRM 3.6 ± 7 8.9 ± 7.6 .390
LFS (%) 89.3 ± 11.6 89.1 ± 8.4 .973
Median Karnofsky score
of survivors‡ (range)
100 (90-100) 100 (90-100) .872
Follow-up in survivor days (range) 1410 (1040-1794) 1522 (1055-1791) .197
aGVHD indicates acute graft-versus-host disease; cGVHD indicates chronic graft-versus-host disease; TRM, treatment-related mortality; LFS, leukemia-
free survival.
*Grade III-IV aGVHD occurred post intervention in the high risk group.
†Patients who survived longer than 100 days after HSCTwere evaluated for cGVHD (high-risk group, n 5 28; low-risk group, n555).
‡Survivors are patients who were alive at the end of this study, October 1, 2009 (high-risk group, n 5 25; low-risk group, n 5 50).
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(grade 1). Eleven patients responded to IM with a me-
dian of 49 days (range: 20-320 days) drug application.
Of the 11 responders, 6 patients had cGVHD , 5 pa-
tients had no GVHD. Two patients showed no re-
sponse to IM, with 102 days and 103 days drug
application. One patient received IM and mDLI on
day 40 after HSCT; she relapsed on day 79 and died
of relapse on day 220 after HSCT. The other patient
received IS-W on day 77, IM on day 201, mDLI on
day 260, relapsed on day 240, and died of relapse on
day 360.
Six patients received 1 or 2 rounds ofmDLI. Except
the just mentioned 2 patients, the other 4 patients had
response to intervention. One patient developed grade
II aGVHD, which was well controlled easily with
methylprednisolone.Nocases of pancytopeniaoccurred
(Table 2).Change in BCR-ABLmRNA after HSCTand
Intervention
In the high-risk group, 2 patients had no response
as shown before. One patient had stable molecular dis-
ease after intervention (IS-W), but developed graft
failure; this patient received a second transplant and
has remained leukemia free 3 years after the second
transplantation. The remaining 25 (89.3%) patients
achieved CMR at a median of 49 days (range: 18-232
days) after intervention and remained in CMR with
a 1427.5 (1040-1794) days follow-up. The median
BCR-ABL level reached undetectable within 2 months
of intervention (Figure 1).
Of the 13 patients who received IM for interven-
tion, 11 achieved CMR a median of 60 days (range:
18-232 days) from the initiation of IM therapy and
had remained in CMR for a median of 1164 days
(range: 896-1598 days) after cessation of IM therapy.
All surviving patients remained in CMR after a follow-
up of median 1481 (1040-1794) days.In the low-risk group patients (n5 56), the level of
BCR-ABL transcripts decreased to an undetectable
median of 4 months post-HSCT; these patients except
1 remained in CMR after a median follow-up of 1522
(1055-1791) days.
GVHD, relapse, and TRM
The overall cumulative incidence of grade III-IV
aGVHD on day 100 was 9.3% 6 3.4%. The 4-year
cumulative incidence of extensive cGVHDwas 29.146
8.35% (n5 83).
The cumulative incidences of grade II-IV aGVHD
on day 100 in the high-risk and low-risk cohorts were
24.3% 6 8.5% and 24.4% 6 5.9%, respectively (P 5
.917). The cumulative incidences of extensive cGVHD
in the high-and low-risk group were 28.57%6 8.54%
and 29.36% 6 6.18%, respectively (P 5 .643). Three
patients died of severe aGVHD in the low-risk group,
whereas no patients died of GVHD in the high-risk
group.
Three patients had hematologic relapse: 2 in the
high-risk group, 1 in the low-risk group. The overall
4-year relapse rate was 3.9% 6 4.4%.
One patient in the high-risk group died of severe
pneumonia. In the low-risk group, 1 patient died of
CMV-related interstitial pneumonia and another 1
died of idiopathic pneumonia syndrome; 3 patients
died of severe aGVHD.The 4-yearTRMwas 3.60%6
7% in the high-risk group and 8.9%6 7.6% in the low-
risk group (Table 3) (P 5 .390).
OS and LFS
Up to the last follow-up of 1443(69-1794) days
posttransplant, 9 patients died. The 4-year OS was
89.0% 6 7% and 4-year current LFS was 89.2% 6
6.8%. The 4-year current LFS was 89.3% 6 11.6%
in the high-risk group and 89.1% 6 8.4% in the low
risk group (P 5 0.774, Figure 2). The surviving pa-
tients had a median Karnofsky score of 100 (range:
90-100).
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Figure 1. Changes in BCR-ABL transcript levels pre and post interven-
tion (n 5 28).
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Allogeneic HSCT has been an established treat-
ment for patients with CML for more than 2 decades.
Data from the International Bone Marrow Transplant
Registry between 1994 and 1999 show 69% 6 2%
survival for 2876 patients transplanted within the first
year of diagnosis and 57% 6 3% survival for 1391
patients transplanted later than 1 year after diagnosis
[22]. The European Group for Blood and Marrow
Transplantation reported an OS of 47% 8 years for
947 patients undergoing an matched sibling donor
transplantation during the first chronic phase [3,5].
A subset of patients who had received standard
GVHD prophylaxis using CsA and MTX (n 5 238)
experienced an OS of 64% at 8 years. In our study, 4-
year OS was 89% 6 7%, LFS was 89.2% 6 6.8%,
the rate of relapse was 3.9%, and surviving patients
remain in CMR and had a median Karnofsky score of
100 despite the fact that 8 patients had advanced-stageFigure 2. Leukemia-free survival of high-risk (n 5 28) and low risk
(n 5 56) patients (P 5 .774)disease prior to HSCT. These excellent outcomes
may be related to (1) the prolonged and intensive
GVHD prophylaxis regimen that was associated with
a low incidence of severe aGVHD, and (2) most impor-
tantly, the risk-adapted individualized intervention
strategy based on early evaluation BCR-ABL transcript
kinetics reduced the risk of relapse while minimizing
TRM. All these data indicate that HSCT can remain
to play an important role in the therapy of CML even
in the ear of antityrosine kinase therapy.
Olavarria et al. [11] suggested that early (3-5
months) detection of BCR-ABL transcripts by real-
time Q-RT/PCR was associated with an increased
risk of relapse following allogeneic SCT, the 3-year
cumulative incidence of relapse was 16.7%, 42.9%,
and 86.4% in the early RT-PCR negative, low posi-
tive, highly positive group respectively (P 5 .0001).
Lange et al. [23] showed that predictors for relapse
were advanced disease stage (P5 .02) and slow reduc-
tion of BCR-ABL transcripts at day 28 (P 5 .006) and
day 56 (P 5 .047) posttransplant with nonmyeloabla-
tive conditioning. The fact that only 1 patient relapsed
in the low-risk group and low-risk patients have an ex-
cellent prognosis indicates that we have successfully
defined the CML patients who did not require post-
HSCT intervention and these intervention criteria
are valid [13-15]. In our study, interventions were
limited to the high-risk patients (28/84). Patients
response to intervention very well and the trend of in-
creasing BCR-ABL transcript levels in the high-risk
group was reversed through the interventions and
the extremely low relapse rate in our patient compared
to references suggest that the individualized interven-
tion strategy reduced the risk of relapse [2-4], although
we have no information about the relapse rate for high-
risk patients who do not receive intervention.
Cessation of immunosuppressant therapy and DLI
are associated with GVHD or BM suppression [24];
however, in our patients with intervention, no severe
GVHD, and pancytopenia occurred and only 1 of 28
patients died of intervention-related infection, thus
demonstrating the safety of the interventions used in
this study. This may be because of (1) patients with
high risk of relapse tend to have lower incidence of
GVHD; (2) IM and mDLI instead of traditional DLI
were applied for intervention. The mDLI procedure
appears to work in these patients but it is unclear
whether therapy with a TKI may acheive better results
or not; therefore, a randomized intervention trial may
be required to compare between these 2 postallogeneic
stem cell transplantation therapeutic interventions.
Our previous data have demonstrated that mDLI is
a safe and effective therapy both for the prophylaxis
and treatment of relapse [8,9]. Olavarria et al. [25] re-
ported that posttransplant IM therapy was a safe and
effective strategy for postponing immunotherapy in
patients undergoing reduced-intensity allograft for
Biol Blood Marrow Transplant 17:649-656, 2011 655Intervention Guided by BCR-ABLTranscript KineticsCML. In our study, intervention-related GVHD
occurred in 16 of 22 patients who received IS-W;
therefore, IS-W might be inferior to IM in safety.
The best protocol of intervention and the precise
duration of IM therapy remains to be determined.
The low relapse rate (3.9%) in this trial is indica-
tive of the benefits of targeted intervention and the
89.2% LFS shows that our strategy resulted in a better
prognosis for the whole group of patients. In short, the
results of this trial confirm the hypothesis described
earlier.
In summary, our results suggest that posttrans-
plant individualized intervention based on serial mon-
itoring of BCR-ABL transcripts can decrease the rate of
relapse and improve LFS in patients with CML. The
strategy used herein can be used as a reference for
the prophylaxis of relapse of other high-risk hemato-
logic malignancies, such as Ph-positive acute lympho-
cytic leukemia and advanced leukemia after HSCT.ACKNOWLEDGMENTS
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